Market Report, "Secukinumab (Rheumatoid Arthritis) Forecast And Market Analysis", Published


New Pharmaceuticals research report from GlobalData is now available from Fast Market Research


Published on 12 February 2013


by Bill Thompson

(WireNews+Co)

Boston, MA

GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Novartis is developing a novel, subcutaneous, fully-human mAb IL-17A inhibitor, known as secukinumab (or AIN457), which is in Phase III clinical trials in various countries including US, EU, and Japan. It promotes inflammatory responses as it neutralizes IL-17A, resulting in the prevention of bone loss. Secukinumab is currently in clinical development for RA as well as for Crohn's disease, MS, psoriatic arthritis, ankylosing spondylitis, and psoriasis.

View Full Report Details and Table of Contents (http://www.fastmr.com/prod/529865_secukinumab_rheumatoid_arthritis_forecast_and.aspx?afid=201)

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Secukinumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Secukinumab for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Secukinumab performance
- Obtain sales forecast for Secukinumab from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia).


Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget.  For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.


Contacts

  •  
  • Bill Thompson
  • Fast Market Research, Inc.
  • PR Contact
  • Tel: +14134857001
  •  
Enter your email:
Enter Subject:
Enter your message:
Please enter this numbers in the fields:
 
  Click image to get a new code.
Enter code:
 

Posted 2013-02-12 16:04:00